Secukinumab B

• Description:

  Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.

• Stability:

  ≥ 2 years

• Purity:

  >98% (HPLC)

• Molecular Formula:

  ——

• Notes:

  Research use only, not for human use.

• Receptor:

  IL Receptor

• CAS Number:

  1229022-83-6